Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Real-world multi-country study of BRCA1/2 mutation testing among adult women with HER2-negative advanced breast cancer.

Future oncology (London, England) - 1 Mar 2022

Lux Michael P, Lewis Katie, Rider Alex, Niyazov Alexander

Abstract excerpt

Aim: We assessed real-world patient demographics and BRCA1/2 mutation testing rates among adult women with HER2-negative advanced breast cancer (ABC). Methods: Oncologists across the USA and in France, Germany, Italy, Spain and the UK provided medical chart data in 2015 and 2017. Results: Overall, 28% of patients received BRCA1/2 mutation testing. Untested patients were more likely to be aged ≥45 years, have...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age Factors
Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Europe

Share to Medical Records

Share to Receptor, ErbB-2

Share to United States

Source

Identifiers

PMID: 35098723
DOI: 10.2217/fon-2021-1387

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-world multi-country study of BRCA1/2 mutation testing among adult women with HER2-negative advanced breast cancer.PMID 35098723Read ↗

BRCA1/2 Mutation Testing Among Adult Women With HER2-Negative Advanced Breast Cancer: Results From a Multi-Country, Real-World StudySemantic proximity Read ↗

Real-World Study of Regional Differences in Patient Demographics, Clinical Characteristics, and BRCA1/2 Mutation Testing in Patients with Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in the United States, Europe, and Israel.Semantic proximity Read ↗

Genetic testing in women with breast cancer: implications for treatment.Semantic proximity Read ↗

BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study.Semantic proximity Read ↗

Racial and Ethnic Differences in BRCA1/2 and Multigene Panel Testing Among Young Breast Cancer Patients.Semantic proximity Read ↗

Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing.Semantic proximity Read ↗

Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline.Semantic proximity Read ↗

<em>BRCA1/2</em> Testing Landscape in Ovarian Cancer: A Nationwide, Real-World Data StudySemantic proximity Read ↗

Association of Genetic Testing Results With Mortality Among Women With Breast Cancer or Ovarian Cancer.Semantic proximity Read ↗

Genetic testing in privately insured women with surgically treated breast cancer.Semantic proximity Read ↗

Which Patients Do We Need to Test for BRCA1/2 Mutation? Feasibility of Adjuvant Olaparib Treatment in Early Breast Cancer–Real-World Data from Two Large German Breast CentersSemantic proximity Read ↗

Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.